Jazz Pharmaceuticals PLC (JAZZ) Receives Consensus Rating of “Buy” from Brokerages
Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) have received an average recommendation of “Buy” from the twenty-seven brokerages that are presently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and nineteen have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $180.79.
JAZZ has been the topic of several research reports. Stifel Nicolaus reissued a “buy” rating and set a $190.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, October 26th. Piper Jaffray Companies set a $177.00 target price on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, October 21st. Zacks Investment Research downgraded shares of Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, November 10th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $195.00 target price (down from $210.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, November 8th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Tuesday, August 29th.
In other Jazz Pharmaceuticals news, Director Patrick G. Enright sold 9,000 shares of the business’s stock in a transaction on Monday, December 11th. The shares were sold at an average price of $139.73, for a total transaction of $1,257,570.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $150.00, for a total transaction of $150,000.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 18,552 shares of company stock worth $2,549,643. Insiders own 4.30% of the company’s stock.
Jazz Pharmaceuticals (NASDAQ:JAZZ) opened at $135.53 on Friday. The company has a market cap of $8,430.84, a P/E ratio of 17.65, a price-to-earnings-growth ratio of 0.91 and a beta of 0.98. Jazz Pharmaceuticals has a one year low of $104.82 and a one year high of $163.75. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.94 and a current ratio of 3.10.
ILLEGAL ACTIVITY WARNING: “Jazz Pharmaceuticals PLC (JAZZ) Receives Consensus Rating of “Buy” from Brokerages” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/16/jazz-pharmaceuticals-plc-jazz-receives-consensus-rating-of-buy-from-brokerages.html.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.